טוען...
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left‐Sided RAS/BRAF Wild‐Type Colorectal Cancer: Which “Side” Are You On?
This commentary focuses on the results of the study by Pietrantonio et al., which evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left‐sided RAS/BRAF wild‐type colorectal cancer and appears in this issue. Both FOLFOXIRI [flu...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Inc.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018293/ https://ncbi.nlm.nih.gov/pubmed/33539032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13705 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|